Comment on The Food and Drug Administration (FDA) Request for Comments: Drug Abuse and Dependence Section of Labeling for Human Prescription Drug and Biological Products — Content and Format; Draft Guidance for Industry, FDA-2019-D-1917-0001 (Jul. 2, 2019)